H. Spahn‐Langguth

1.6k total citations
43 papers, 1.2k citations indexed

About

H. Spahn‐Langguth is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, H. Spahn‐Langguth has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 16 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in H. Spahn‐Langguth's work include Drug Transport and Resistance Mechanisms (16 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Analytical Chemistry and Chromatography (11 papers). H. Spahn‐Langguth is often cited by papers focused on Drug Transport and Resistance Mechanisms (16 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Analytical Chemistry and Chromatography (11 papers). H. Spahn‐Langguth collaborates with scholars based in Germany, Egypt and Austria. H. Spahn‐Langguth's co-authors include Peter Langguth, Abeer Hanafy, Guy Vergnault, P. Grenier, Daniel Wagner, E. Mutschler, Constanze Hilgendorf, Werner Rubas, Heidi Wunderli‐Allenspach and Hans P. Merkle and has published in prestigious journals such as PLoS ONE, Advanced Drug Delivery Reviews and Molecules.

In The Last Decade

H. Spahn‐Langguth

43 papers receiving 1.2k citations

Peers

H. Spahn‐Langguth

ONCOL

PS

PHARM

MB

PPCH

Urban Fagerholm Sweden

Hildegard Spahn‐Langguth Germany

Gloria Y. Kwei United States

Barbra H. Stewart United States

Christer Tannergren Sweden

Kazuhiko Arimori Japan

Jun‐Shik Choi South Korea

Kimberley A. Lentz United States

Charles J. Rotter United States

Oliver Hatley United Kingdom

Urban Fagerholm Sweden

H. Spahn‐Langguth

706 ×1.3

ONCOL

533 ×1.4

PS

369 ×1.1

PHARM

252 ×1.0

MB

215 ×0.9

PPCH

Citations per year, relative to H. Spahn‐Langguth H. Spahn‐Langguth (= 1×) peers Urban Fagerholm

Countries citing papers authored by H. Spahn‐Langguth

Since Specialization

Citations

This map shows the geographic impact of H. Spahn‐Langguth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Spahn‐Langguth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Spahn‐Langguth more than expected).

Fields of papers citing papers by H. Spahn‐Langguth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Spahn‐Langguth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Spahn‐Langguth. The network helps show where H. Spahn‐Langguth may publish in the future.

Co-authorship network of co-authors of H. Spahn‐Langguth

This figure shows the co-authorship network connecting the top 25 collaborators of H. Spahn‐Langguth. A scholar is included among the top collaborators of H. Spahn‐Langguth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Spahn‐Langguth. H. Spahn‐Langguth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Lang, Berenice M., Petra Staubach, Stephan Grabbe, et al.. (2023). Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product. Pharmaceutics. 15(2). 514–514. 12 indexed citations

2.

Zaghloul, Ashraf, et al.. (2017). Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients. Oncology Reports. 38(1). 551–560. 3 indexed citations

3.

Okyar, Alper, et al.. (2012). Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance. Chronobiology International. 29(4). 443–453. 30 indexed citations

4.

Abdel‐Haleem, Alyaa M., et al.. (2011). Expression of RFC/SLC19A1 is Associated with Tumor Type in Bladder Cancer Patients. PLoS ONE. 6(7). e21820–e21820. 14 indexed citations

5.

Hanafy, Abeer, et al.. (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug☆. Advanced Drug Delivery Reviews. 59(6). 419–426. 167 indexed citations

6.

Langguth, Peter, et al.. (2005). Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound. Drug Development and Industrial Pharmacy. 31(3). 319–329. 80 indexed citations

7.

Wolffram, Siegfried, et al.. (2005). Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?. European Journal of Pharmaceutical Sciences. 25(2-3). 263–271. 74 indexed citations

8.

Mühlberg, W., et al.. (2001). The influence of age on the pharmacokinetics and pharmacodynamics of bemetizide and triamterene: a single and multiple dose study. Archives of Gerontology and Geriatrics. 32(3). 265–273. 8 indexed citations

9.

Spahn‐Langguth, H. & Peter Langguth. (2001). Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. European Journal of Pharmaceutical Sciences. 12(4). 361–367. 103 indexed citations

10.

Wagner, Daniel, et al.. (2001). Intestinal drug efflux: formulation and food effects. Advanced Drug Delivery Reviews. 50. S13–S31. 91 indexed citations

11.

Neuhoff, Sibylle, et al.. (2000). Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. International Journal of Clinical Pharmacology and Therapeutics. 38(4). 168–179. 45 indexed citations

12.

Anderle, Pascale, Eva Niederer, Werner Rubas, et al.. (1998). P-Glycoprotein (P-gp) Mediated Efflux in Caco-2 Cell Monolayers: The Influence of Culturing Conditions and Drug Exposure on P-gp Expression Levels. Journal of Pharmaceutical Sciences. 87(6). 757–762. 179 indexed citations

13.

Lipka, Elke, H. Spahn‐Langguth, E. Mutschler, & Gordon L. Amidon. (1998). In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion. European Journal of Pharmaceutical Sciences. 6(1). 75–81. 8 indexed citations

14.

Spahn‐Langguth, H., et al.. (1996). Acyl glucuronides: covalent binding and its potential relevance.. PubMed. 387. 313–28. 18 indexed citations

15.

Mey, Christian de, R. Butzer, Patrick Jahn, et al.. (1995). Dose-Effect and Kinetic-Dynamic Relationships of the (β-Adrenoceptor Blocking Properties of Various Doses of Talinolol in Healthy Humans. Journal of Cardiovascular Pharmacology. 26(6). 879–888. 10 indexed citations

16.

Stahl, Elke, et al.. (1993). Saturable Enantioselective First‐pass Effect for Carvedilol after High Oral Racemate Doses in Rats. Archiv der Pharmazie. 326(3). 123–125. 6 indexed citations

17.

Hahn, Gabriele, et al.. (1993). The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. British Journal of Clinical Pharmacology. 36(4). 363–365. 13 indexed citations

18.

Spahn‐Langguth, H., et al.. (1991). Improved Enantiospecific RP-HPLC Assays for Propranolol in Plasma and Urine with Pronethalol as Internal Standard. Journal of Analytical Toxicology. 15(6). 327–331. 14 indexed citations

19.

Spahn‐Langguth, H., et al.. (1991). Improved Enantiospecific RP-HPLC Assays for Propranolol in Plasma and Urine with Pronethalol as Internal Standard. Journal of Analytical Toxicology. 15(4). 209–213. 11 indexed citations

20.

Hartmann, C., et al.. (1990). Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function. European Journal of Clinical Pharmacology. 39(6). 573–576. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact